RBC Capital Reiterates Outperform on Amgen, Maintains $362 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an 'Outperform' rating for Amgen (NASDAQ:AMGN) and maintained a price target of $362.
September 26, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for Amgen, maintaining a price target of $362, indicating confidence in the company's performance.
The reiteration of an 'Outperform' rating and a maintained price target of $362 by RBC Capital suggests positive sentiment and confidence in Amgen's future performance, likely leading to a short-term positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100